论文部分内容阅读
目的探讨门冬胰岛素30治疗初发2型糖尿病患者的临床效果。方法选取以2015年1月至2016年3月大石桥市中心医院收治的78例初发2型糖尿病患者作为研究对象,按照随机数字表法将患者分为对照组和研究组,各39例。对照组患者给予精蛋白生物合成人胰岛素注射液,研究组患者采用门冬胰岛素30进行治疗,比较两组患者就诊时以及治疗8周后空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(Hb A1)水平及低血糖发生情况、血糖达标时间、全天胰岛素使用剂量。结果治疗后,两组患者的2 h PBG及Hb A1水平均明显低于治疗前,研究组患者的2 h PBG水平明显低于对照组,差异均有统计学意义(均P<0.05);研究组患者低血糖发生率明显低于对照组,血糖达标时间明显短于对照组,差异均有统计学意义(均P<0.05)。结论在初发2型糖尿病临床治疗中,应用门冬胰岛素30不仅能快速高效地控制2型糖尿病患者的血糖水平,减轻高血糖状态对患者身体造成的危害,还能够有效降低用药后低血糖事件的发生。
Objective To investigate the clinical effect of insulin aspart 30 in newly diagnosed type 2 diabetic patients. Methods A total of 78 patients with newly diagnosed type 2 diabetes admitted to Dashiqiao Central Hospital from January 2015 to March 2016 were selected as study subjects. Patients were divided into control group and study group (n = 39) according to random number table method. Patients in the control group were given protamine biosynthesis human insulin injection. Patients in the study group were treated with insulin aspart 30, and fasting blood glucose (FBG), 2 h postprandial blood glucose (2 h PBG ), Glycosylated hemoglobin (Hb A1) levels and hypoglycemia, blood glucose compliance time, all-day insulin dosage. Results After 2 weeks of treatment, the levels of PBG and Hb A1 at 2 h were significantly lower than those before treatment, and PBG levels at 2 h in study group were significantly lower than those in control group (all P0.05) The incidence of hypoglycemia in the group of patients was significantly lower than that in the control group, and the time of reaching the blood glucose level was significantly shorter than that in the control group (all P <0.05). Conclusions In the initial clinical treatment of type 2 diabetes mellitus, insulin aspart 30 can not only quickly and efficiently control the blood sugar level in patients with type 2 diabetes, relieve the harm caused by hyperglycemia to the patient’s body, but also reduce the incidence of hypoglycaemia happened.